News

Human Life CORD Japan Inc. (President and CEO: Masamitsu Harata, Headquarters: Chuo-ku, Tokyo, Japan, hereinafter referred to as “HLC”), aiming to be the pioneer to develop and commercialize umbilical cord-derived mesenchymal stem cells (hereinafter “UC-MSC”) globally as regenerative medicine products, has been working on the international harmonization of manufacturing platform technologies for next-generation UC-MSC in collaboration with New York Blood Center Enterprises. (President and CEO: Christopher D. Hillyer, MD, Headquarters: New York, USA, hereinafter “NYBCe”), under a Memorandum of Understanding (MOU) signed on July 13, 2023.
 
Based on strategic decisions to strengthen its activities in the United States, HLC entered into a new Letter of Intent (LOI) with NYBCe on December 24, 2024 to potentially leverage NYBCe’s resources to accelerate technological evaluations and information sharing, advancing the establishment of manufacturing bases in North and South America.
 
NYBCe, one of the largest independent nonprofit blood banks in the United States, supports the manufacturing of cell and gene therapies through, Comprehensive Cell Solutions (CCS), a business unit of NYBCe.
 
Against this backdrop, in December 2024, the FDA (U.S. Food and Drug Administration) announced the first-ever approval of MSC-based cell therapy in the United States, further raising global expectations for the potential and benefits of MSCs.
 
To promote the broader adoption of cell-based therapies worldwide, the standardization of reliable manufacturing and quality control processes tailored to inte rnational regulations and market needs is essential. HLC’s UC-MSC demonstrates high proliferation capacity, enabling stable and large-scale production. The potential collaboration with NYBCe, which adheres to FDA-compliant manufacturing and quality control processes, is expected to enhance standardization and reliability in manufacturing and quality control, thereby establishing a robust global supply chain.
 
Building on this initiative, HLC is expanding its global footprint, targeting regions such as ASEAN countries, the Middle East, and Africa. HLC is committed to providing treatment options for patients worldwide who require UC-MSCs and to build ecosystems for umbilical cord-derived cell therapies.
 
 
■ About New York Blood Center Enterprises. (NYBCe) https://www.nybc.org/
Founded in 1964, New York Blood Center Enterprises (NYBCe) has provided more than 60 years of lifesaving research, innovation, and impact. NYBCe is one of the largest nonprofit blood centers, spanning 17+ states and serving 75 million people. NYBCe additionally delivers cellular therapies, specialty pharmacy, and medical services to 200+ research, academic, and biopharmaceutical organizations. NYBCe’s Lindsley F. Kimball Research Institute is a leader in hematology and transfusion medicine research, dedicated to the study, prevention, treatment and cure of bloodborne and blood-related diseases. NYBCe is a vital community lifeline dedicated to helping patients and advancing global public health.
 
■About Human Life CORD Japan Inc. https://humanlifecord.com/
Human Life CORD JAPAN Inc. manufactures and develops cell products derived from domestically sourced, storable umbilical cords (“cord”), aiming to connect (“cord”) patients with intractable diseases to hope for life where no established treatments currently exist. Looking ahead, aims to contribute to future medicine that prevents severe disease progression and extends healthy lifespans, creating a society where everyone can enjoy a fulfilling life (“Human Life”).
 
HLC has received numerous accolades, including:
– First Prize and Governor of Tokyo Award at the 1st Tokyo Venture Business Championship (2019)
– Selection as a target company of the “Deep Ecosystem” operated by the Tokyo Metropolitan Government’s Startup Ecosystem Tokyo Consortium
– Minister of Health, Labor, and Welfare Award at the 5th Japan Open Innovation Prize (2023
– Selection for the “J-Startup” program by Japan’s Ministry of Economy, Trade, and Industry (2023)
– Grand Prize in the Startup Category at the Tokyo Chamber of Commerce and Industry’s “Courageous Management Awards” (2024)
 
 
[Contact]
info@humanlifecord.com / +81 80 4671 0405